Influenza Vaccines are the seasonal flu shots that are administered to protect people against influenza infection
Researchers are evaluating flu vaccines based on mRNA technology. mRNA technology allows scientists to swap mRNA encoding different antigens in a single vaccine. The mRNA technology used is foreseen to protect a large portion of the population from COVID-19. Conventional Influenza Vaccines are grown in chicken eggs for months. By contrast, mRNA vaccines are produced relatively quickly. This may improve their match to the flu strain and provoke a stronger immune response than traditional vaccines.
One vaccine that has shown promise is the mRNA-based vaccines developed by French scientists. These vaccines contain a gene that encodes the proteins of rare mutating influenza viruses. Although the vaccine is not universal, experiments in animals show that it may remain effective year after year.
In addition to the egg-based vaccine, recombinant vaccines have become a viable alternative for people with severe egg allergies. They are made from synthetic DNA and do not require egg-growing. For instance, in June 2022, Moderna, a major Influenza Vaccines provider in the U.S., initiated a Phase III study on its mRNA-1010, a seasonal influenza vaccine candidate.
The hemagglutinin protein of the influenza virus is highly variable and is responsible for evading the immune system. The same B cells that respond to the first flu exposure continue to dominate the immune response to new influenza strains. Thus, the hemagglutinins in Influenza Vaccines are constantly changing as new strains are discovered and circulating in the country. This constant evolution also contributes to the low effectiveness of influ vaccines.
In addition to egg-based vaccines, recombinant HA vaccines have several benefits over traditional vaccines. For instance, recombinant HA vaccines can be produced using insect cells. Recombinant HA has the same advantages as cell-based Influenza Vaccines Market, but does not rely on the influenza virus for replication. The process for the production of these vaccines typically takes 68 months. The production process can be delayed significantly due to unforeseen circumstances, such as low virus yields. Furthermore, this long interval of time gives the influenza viruses time to mutate. One late-emerging variant of H3N2 rendered the recommended vaccine strain ineffective.

Comments
Post a Comment